NOVOS Core Supplement Improves Endothelial Function and Lowers Systolic BP by 6.1 mmHg in 6-Month RCT

Researchers randomized 33 participants to daily NOVOS Core and 28 to placebo for six months. They measured endothelial function via flow-mediated dilation, arterial stiffness via pulse wave velocity, and office systolic blood pressure at baseline, one hour post-first dose, and six months. The supplement group showed rapid and sustained gains in these vascular markers while lipid levels remained unchanged. The 6.1 mmHg systolic difference and 1.18 m/s pulse-wave-velocity reduction align with prior observational data linking similar shifts to lower cardiovascular risk, yet the trial was not powered for events. By targeting multiple aging hallmarks simultaneously, the formulation produced effects larger than single-ingredient studies typically report, though the precise active components driving the changes remain unidentified. Professor Christian Heiss noted the need for larger trials to confirm mechanisms and clinical outcomes. The small sample and industry involvement in formulation development limit generalizability; independent replication with hard endpoints such as myocardial infarction or stroke is required before any public-health recommendation.